Sort   by:  
 Page size 
UnknownBortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.
Not available
S-EPMC3577952 | biostudies-literature
UnknownAbdominal infections in the intensive care unit: characteristics, treatment and determinants of outcome.
Not available
S-EPMC4122779 | biostudies-literature
UnknownSARS-CoV-2 infection increases risk of acute kidney injury in a bimodal age distribution.
Not available
S-EPMC8831033 | biostudies-literature
UnknownTwo phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Not available
S-EPMC4159618 | biostudies-literature
UnknownAssociation of Renin Angiotensin Aldosterone System Inhibitors and Outcomes of Hospitalized Patients With COVID-19.
Not available
S-EPMC9469914 | biostudies-literature
UnknownIdentical and Nonidentical Twins: Risk and Factors Involved in Development of Islet Autoimmunity and Type 1 Diabetes.
Not available
S-EPMC6341285 | biostudies-literature
UnknownA Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk.
Not available
S-EPMC6105323 | biostudies-literature
UnknownConvalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial.
Not available
S-EPMC8121538 | biostudies-literature
Sort   by:  
 Page size